Salmeterol/Fluticasone Propionate FDC
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Salmeterol/Fluticasone Propionate FDC, covering 2019-04-29 to 2019-04-29. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD [Phase 4]